As fears of a po­lit­i­cal­ly-mo­ti­vat­ed vac­cine EUA grow, Er­ic Topol de­liv­ers an ul­ti­ma­tum to com­mis­sion­er Hahn: Stand up or re­sign

3 weeks ago
Coronavirus

Covid-19 roundup: As­traZeneca launch­es 3rd US PhI­II vac­cine study with a vow to avoid 'cut­ting cor­ner­s'

3 weeks ago
Coronavirus

Sanofi, Re­gen­eron hit fi­nal nail on the IL-6 re­pur­pos­ing cof­fin as Kevzara fails PhI­II

3 weeks ago
R&D
Coronavirus

No­var­tis says its Soliris add-on might be able to re­place the Alex­ion drug al­to­geth­er. But is it too late?

3 weeks ago
R&D

A three-year ex­per­i­ment comes to an end, as Io­n­is re­ab­sorbs Akcea for $500M

3 weeks ago
Deals

Un­fazed by slow roll­out, Nestlé buys out Aim­mune and its peanut al­ler­gy med for $2.6B

3 weeks ago
Deals

Covid-19 roundup: Most Amer­i­cans wor­ry pol­i­tics is put be­fore sci­ence amid vac­cine rush; Dai­ichi Sankyo fur­thers mR­NA shot R&D

3 weeks ago
Coronavirus

Akcea shows off what No­var­tis missed and what Pfiz­er gained, of­fer­ing more de­tails on PhII car­dio da­ta

3 weeks ago
R&D

FDA com­mis­sion­er Hahn ousts agency’s new chief spokesper­son as plas­ma con­tro­ver­sy con­tin­ues to smol­der

3 weeks ago
People
Coronavirus

Of­fers upped and upped again, CEO-to-CEO calls and per­haps a veiled walk­out threat: In­side Sanofi CEO Paul Hud­son's first big buy­out

3 weeks ago
Deals

Michael Var­ney comes out of brief Genen­tech 're­tire­men­t' for R&D gig at Eras­ca; Vivek Ra­maswamy's Im­muno­vant re­cruits J&J vet for CSO post

3 weeks ago
Peer Review

Covid-19 roundup: J&J launch­ing new PhII vac­cine tri­als in Eu­rope; Ab­bott scores $760M test­ing kit or­der from HHS

3 weeks ago
Coronavirus

Trump promis­es a safe, ef­fec­tive vac­cine for Covid-19 be­fore year’s end — 'or maybe even soon­er!' So where does that leave the FDA?

3 weeks ago
Bioregnum
Coronavirus

That pipeline Ab­b­Vie ac­quired in the $63B Al­ler­gan buy­out? It’s not do­ing so well

4 weeks ago
R&D

Covid-19 roundup: BeiGene snags rights to po­ten­tial an­ti­body treat­ment; Beef­ing up man­u­fac­tur­ing ops, Re­gen­eron adds 400 jobs at Irish fa­cil­i­ty

4 weeks ago
Coronavirus

FDA com­mish Hahn spot­lights Oct 22 vac­cine ad­vi­so­ry meet­ing as the next big flash­point in the Covid-19 cam­paign

4 weeks ago
Bioregnum
Coronavirus

Mod­er­na takes one more step along the high-wire act of Covid-19 vac­cine work, of­fer­ing mark­ers of suc­cess for the most vul­ner­a­ble age group

4 weeks ago
R&D
Coronavirus

Vivek Ra­maswamy’s Der­ma­vant team looks to take on Am­gen’s $13.4B pso­ri­a­sis con­tender Ote­zla with a promis­ing PhI­II read­out for a top­i­cal ri­val

4 weeks ago
R&D

Covid-19 roundup: Eu­ro­pean vac­cines lob­by push­ing for li­a­bil­i­ty pro­tec­tion; VBI vac­cines to prep hu­man tri­als

4 weeks ago
Coronavirus

No­var­tis finds a third-gen­er­a­tion scion to an ag­ing Gleevec, suc­cess­ful­ly tak­ing on a Pfiz­er ri­val for last-chance CML pa­tients

4 weeks ago
R&D

Agios just sold off the roy­al­ty rights for $255M, but Bris­tol My­ers says Id­hi­fa was a bust in PhI­II. Now what?

4 weeks ago
R&D

Covid-19 roundup: Bio­gen con­fer­ence is tied to tens of thou­sands of Covid-19 cas­es; FDA chief Stephen Hahn walks back plas­ma com­ments

4 weeks ago
Coronavirus

Ex­clu­sive: We asked for bio­phar­ma's opin­ion about the plas­ma EUA. The in­dus­try of­fered a dou­ble-bar­reled re­sponse

4 weeks ago
Regulatory
Coronavirus

Bris­tol My­ers hun­kers down at the deals ta­ble, ex­e­cut­ing a new I/O play in biotech buy­out

4 weeks ago
Deals
First page Previous page 123456 Next page Last page